Antimicrobial Susceptibility among Pathogens Isolated in Early- versus Late-Onset Ventilator-Associated Pneumonia.
MDR
VAP
antibiotic therapy
causative pathogens
Journal
Infectious disease reports
ISSN: 2036-7430
Titre abrégé: Infect Dis Rep
Pays: Switzerland
ID NLM: 101537203
Informations de publication
Date de publication:
27 Apr 2021
27 Apr 2021
Historique:
received:
18
03
2021
revised:
20
04
2021
accepted:
23
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Ventilator-associated pneumonia (VAP) is associated with increased hospital stay and high morbidity and mortality in critically ill patients. The aims of this study were to (i) determine the incidence of multidrug-resistant (MDR) pathogens in the first episodes of VAP and to assess potential differences in bacterial profiles of subjects with early- versus late-onset VAP. This was a retrospective cohort study over a period of 18 months including all patients who had a first episode of VAP confirmed by positive bacterial culture. Subjects were distributed into two groups according to the number of intubation days: early-onset VAP (<5 days) or late-onset VAP (≥5 days). The primary endpoint was the nature of causative pathogens and their resistance profiles. Sixty patients were included, 29 men and 31 women, with an average age of 38 ± 16 years. The IGS 2 at admission was 40.5 [32-44] and APACHE was 19 [15-22]. Monomicrobial infections were diagnosed in 77% of patients (
Identifiants
pubmed: 33925385
pii: idr13020038
doi: 10.3390/idr13020038
pmc: PMC8167786
doi:
Types de publication
Journal Article
Langues
eng
Pagination
401-410Subventions
Organisme : Centre d'Assistance Médicale Urgente of Tunis
ID : CAMU
Références
BMJ. 2012 May 29;344:e3325
pubmed: 22645207
J Crit Care. 2008 Mar;23(1):91-100
pubmed: 18359426
J Infect Chemother. 2007 Dec;13(6):400-4
pubmed: 18095089
Intensive Care Med. 2005 Nov;31(11):1488-94
pubmed: 16151723
Am J Respir Crit Care Med. 1998 Feb;157(2):531-9
pubmed: 9476869
Surg Clin North Am. 2012 Dec;92(6):1519-57
pubmed: 23153883
Am Rev Respir Dis. 1989 Apr;139(4):877-84
pubmed: 2930067
Australas Med J. 2013 Sep 30;6(9):430-4
pubmed: 24133535
Intensive Care Med. 2004 Feb;30(2):217-224
pubmed: 14566455
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Crit Care Med. 2015 Mar;43(3):527-33
pubmed: 25493971
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Am J Infect Control. 2011 Dec;39(10):798-816
pubmed: 22133532
J Antimicrob Chemother. 2015 Jan;70(1):23-40
pubmed: 25261423
Tuberc Respir Dis (Seoul). 2012 Jul;73(1):32-7
pubmed: 23101022
Respir Care. 2013 Jul;58(7):1220-5
pubmed: 23307825
Curr Opin Crit Care. 2014 Oct;20(5):516-24
pubmed: 25188366
Microb Drug Resist. 2019 Nov;25(9):1282-1286
pubmed: 31361568
JAMA. 1995 Aug 23-30;274(8):639-44
pubmed: 7637145
Chest. 2002 May;121(5):1618-23
pubmed: 12006452
Intensive Care Med. 2013 Apr;39(4):672-81
pubmed: 23358539
Lancet Infect Dis. 2013 Aug;13(8):665-71
pubmed: 23622939
Infect Control Hosp Epidemiol. 2010 May;31(5):509-15
pubmed: 20302428
Clin Infect Dis. 2001 Nov 1;33(9):1462-8
pubmed: 11588690
Am J Respir Crit Care Med. 1996 May;153(5):1711-25
pubmed: 8630626
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
Chest. 1997 Mar;111(3):676-85
pubmed: 9118708
Antimicrob Agents Chemother. 2015 Nov;59(11):7100-3
pubmed: 26303798
Microbiol Mol Biol Rev. 2015 Mar;79(1):101-16
pubmed: 25652543
Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903
pubmed: 11934711
Am J Respir Crit Care Med. 1999 Aug;160(2):608-13
pubmed: 10430736
Ann Intern Med. 1972 Nov;77(5):701-6
pubmed: 5081492
Chest. 2005 Aug;128(2):533-44
pubmed: 16100135
J Clin Diagn Res. 2013 Nov;7(11):2462-6
pubmed: 24392373
Curr Infect Dis Rep. 2015 Aug;17(8):496
pubmed: 26115700
J Crit Care. 2008 Mar;23(1):5-10
pubmed: 18359415
J Ayub Med Coll Abbottabad. 2015 Jan-Mar;27(1):117-9
pubmed: 26182754
Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S81-7
pubmed: 20597676
Crit Care Med. 2005 Oct;33(10):2184-93
pubmed: 16215368